Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Average Rating of “Buy” from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $46.4286.

A number of analysts recently issued reports on AAPG shares. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth approximately $391,000. XY Capital Ltd boosted its position in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the last quarter. Finally, UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Stock Performance

NASDAQ:AAPG opened at $19.24 on Wednesday. The firm has a 50 day simple moving average of $18.87 and a 200-day simple moving average of $22.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 1-year low of $16.36 and a 1-year high of $48.45.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.